Fulvestrant Improves Survival Over Anastrozole for Patients with Advanced Breast Cancer

December 16, 2014

According to a phase II trial presented at the 2014 San Antonio Breast Cancer Symposium, patients with advanced, hormone receptor-positive breast cancer who had not been already been treated for advanced disease lived longer after taking fluvestrant than those treated with anastrozole. Patients treated with fluvestrant were “30% less likely to die of their disease compared with those who took anastrozole.” The side effects for the treatments were similar. A phase III study is currently underway to further compare the outcomes of the two treatments. Read more here.  

If you or a loved one has been diagnosed with breast cancer, visit My PearlPoint and sign up for a FREE dashboard to download the Breast Cancer Handbook, your ultimate guide through treatment and survivorship.